Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUO-E trial of durvalumab with chemotherapy followed by maintenance durvalumab with or without olaparib in advanced or recurrent endometrial cancer
2019-004112-60Phase 3Active
- Sponsor
- AstraZeneca
- Start
- May 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of durvalumab, olaparib, carboplatin and paclitaxel in endometrial cancer (EC) (3 arms), sponsored by AstraZeneca. Primary endpoint: Progression-free survival. Started May 2020; status: active.
02
Drugs
durvalumabolaparibcarboplatinpaclitaxel
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on 2019-004112-60.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004112-60.